New Meningococcal Meningitis Vaccine Offered in South Africa Johannesburg, South Africa — In a significant development in the realm of public health, a new meningococcal meningitis vaccine is now available in South Africa.
The vaccine, which targets four types of meningococcal bacteria — A, C, W, and Y—aims to provide protection against the potentially life-threatening disease.
The vaccine is recommended for children from 12 months of age, adolescents, and adults.
According to the National Institute for Communicable Diseases, South Africa recorded 148 cases of invasive meningococcal disease in 2025. Of these, 35% involved children under five years old, while 26% were recorded among children and adolescents aged five to 17.
The disease is caused by the bacterium Neisseria meningitidis, which can lead to meningitis, a serious inflammation of the protective membranes surrounding the brain and spinal cord, or sepsis, a severe infection in the bloodstream.
The new vaccine, which is part of the country’s routine immunization program, has been confirmed by the Western Cape Department of Health and Wellness.
As of February 2026, the department reported 11 confirmed meningococcal disease cases, including one death, in the Western Cape province. Experts from the South African Medical Research Council (SAMRC) emphasize the importance of early detection and routine health screenings for the disease.
They suggest that the new vaccine is a crucial step towards reducing the burden of meningococcal meningitis in the country.
Parents and caregivers are advised to discuss the vaccine with their healthcare providers to ensure their families are protected.
The vaccine is available at various public health facilities and private clinics across the country.
The SAMRC advises maintaining vigilance for the disease’s symptoms, which may include fever, headache, stiff neck, and confusion.
As South Africa continues to grapple with the challenges posed by meningococcal meningitis, the introduction of this new vaccine is a positive step towards reducing the incidence of the disease and protecting vulnerable populations, particularly children.
As the vaccine rolls out, experts will continue to monitor its effectiveness and the impact it has on meningococcal meningitis cases in South Africa.
The WHO also offers guidance and resources to help countries implement meningococcal vaccination programs. This development marks an important milestone in the fight against meningococcal meningitis in South Africa, offering a glimmer of hope for those affected by the disease and a significant advancement in public health efforts.
*Additional reporting by ImNews | Sources consulted: 5*
—
This original article was produced by the ImNews editorial team
Source: Google News v2
